CN Patent

CN107427516B8 — 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法

Assigned to Oncoceutics Inc · Expires 2021-04-09 · 5y expired

What this patent protects

本公开涉及使用化合物(1)或其类似物、及其药学上可接受的盐治疗的方法。还公开说明书中限定的式(10)的化合物、及其药学上可接受的盐、以及包含其的药物组合物。提供了诸如癌症的治疗方法，其包括向需要这种治疗的受试者施用化合物及其盐。

USPTO Abstract

本公开涉及使用化合物(1)或其类似物、及其药学上可接受的盐治疗的方法。还公开说明书中限定的式(10)的化合物、及其药学上可接受的盐、以及包含其的药物组合物。提供了诸如癌症的治疗方法，其包括向需要这种治疗的受试者施用化合物及其盐。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN107427516B8
Jurisdiction: CN
Classification: —
Expires: 2021-04-09
Drug substance claim: No
Drug product claim: No
Assignee: Oncoceutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.